Prednisone
Prednisone · oral tablet
Steroid
Approved uses
Severe ocular inflammatory and allergic disease, including diffuse posterior uveitis and choroiditis, iritis and iridocyclitis, chorioretinitis, keratitis, and sympathetic ophthalmia
5 to 60 mg PO daily initially, by disease entity and severity (selected patients may require higher initial doses), taken in the morning before 9 am, then reduced in small increments to the lowest maintenance dose that holds the response.
Adrenal suppression lasts only 1.25 to 1.5 days after a single dose, making alternate-day dosing feasible.
OFF-LABELNot in the FDA label for this product
Giant cell arteritis, including arteritic anterior ischemic optic neuropathy
High-dose oral prednisone begun the day of suspicion, before temporal artery biopsy: 80 to 120 mg daily in Hayreh's series, or 60 to 80 mg daily by body weight after methylprednisolone 1 g IV daily for 3 days in the Danesh-Meyer vision-loss protocol.
Case series · n=144
Hayreh's noncomparative interventional case series of 144 biopsy-proven patients (271 eyes) found further acuity loss in 9 of the 91 who presented with visual loss and in none of the 53 who presented without it, and every deterioration began within 5 days of starting high-dose steroid; IV megadose was not more effective than oral (6 of 48 versus 3 of 97, P = 0.060). A prospective multicenter series of 34 patients given 1 g IV methylprednisolone daily for 3 days then oral prednisone still lost vision in 27% of eyes during the first week, while 15% of eyes gained acuity within the first month with matching visual field gain in only 5%. The 2021 ACR/VF guideline conditionally prefers pulse IV glucocorticoid over high-dose oral when vision loss is threatened, high-dose oral when there is no cranial ischemia, and daily over alternate-day dosing; only 2 of the guideline's 42 GCA and Takayasu arteritis recommendations are strong, and the rest are conditional on low-quality evidence.
IV methylprednisolone followed by an 11-day oral prednisone course, the ONTT regimen for acute demyelinating optic neuritis
Prednisone 1 mg/kg PO daily for 11 days following methylprednisolone 250 mg IV every 6 hours for 3 days, then a short taper, as given in the Optic Neuritis Treatment Trial.
RCT · n=457 · no acuity gain
The ONTT randomized 457 patients to IV methylprednisolone then oral prednisone, to oral prednisone 1 mg/kg daily alone for 14 days, or to placebo. The IV-then-oral arm recovered visual function faster, with only marginal differences remaining at 6 months and no acuity benefit; the oral-alone arm did not differ from placebo and had a higher rate of new optic neuritis episodes in either eye (relative risk 1.79 versus placebo, 95% CI 1.08 to 2.95). At 1 year the investigators concluded that oral prednisone alone, in the dose range used, should not be prescribed.
Contraindications
- Systemic fungal infections
- Known hypersensitivity to components
5 mg, 10 mg and 20 mg tablets; 5 mg and 10 mg in bottles of 100 and 1000 tablets; 20 mg in bottles of 100, 500 and 1000 tablets
Prednisone is a glucocorticoid, an adrenocortical steroid readily absorbed from the gastrointestinal tract. Synthetic glucocorticoids are used primarily for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects and modify the body's immune responses to diverse stimuli. Prednisone is considered short acting (producing adrenocortical suppression for 1 1/4 to 1 1/2 days following a single dose), so it is recommended for alternate day therapy; dexamethasone and betamethasone are not recommended for it because of their prolonged suppressive effect on adrenal activity.
Warnings & Precautions
- Optic neuritis: Oral corticosteroids are not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes.
- Cataract, glaucoma, and ocular infection: Corticosteroid use may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves, and may enhance establishment of secondary bacterial, fungal, or viral ocular infection.
- Corneal perforation: Corticosteroids should not be used in active ocular herpes simplex because of possible corneal perforation.
- Elevated intraocular pressure: Intraocular pressure may become elevated in some individuals; if steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.
- Anaphylactoid reactions: Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy.
- General: Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during and after the stressful situation.
- HPA axis suppression: Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal. This relative insufficiency may persist for up to 12 months after discontinuation, so hormone therapy should be reinstituted in any stress during that period, and a patient already on steroids may need a higher dose. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be given concurrently.
- Adrenocortical insufficiency: Adrenocortical insufficiency may result from too rapid withdrawal and may be minimized by gradual reduction of dosage. Patients should not discontinue corticosteroids abruptly or without medical supervision. After prolonged therapy, withdrawal may cause the corticosteroid withdrawal syndrome, including myalgia, arthralgia, and malaise.
- Metabolic clearance: Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients, and changes in thyroid status may necessitate dosage adjustment. There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis.
- Infection: Patients on corticosteroids are more susceptible to infections than are healthy individuals, and there may be decreased resistance and inability to localize infection. Infection with any pathogen in any location may occur; these infections may be mild, but may be severe and at times fatal. The rate of infectious complications increases with increasing doses, and corticosteroids may mask some signs of current infection.
- Fungal infections: Corticosteroids may exacerbate systemic fungal infections and should not be used in their presence unless needed to control life-threatening drug reactions. There have been cases reported in which concomitant amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
- Special pathogens: Latent disease may be activated, or intercurrent infections exacerbated, by pathogens including Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis and Toxoplasma. Rule out latent or active amebiasis before therapy in any patient who has spent time in the tropics or has unexplained diarrhea. Corticosteroids should not be used in cerebral malaria.
- Strongyloides hyperinfection: Use corticosteroids with great care in known or suspected Strongyloides (threadworm) infestation, because corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination, often with severe enterocolitis and potentially fatal gram-negative septicemia.
- Tuberculosis: In active tuberculosis, restrict prednisone to fulminating or disseminated tuberculosis managed with an appropriate antituberculous regimen. In latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation may occur, and these patients should receive chemoprophylaxis during prolonged therapy.
- Vaccination: Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, but the response may be diminished and cannot be predicted.
- Serious or fatal chickenpox and measles: Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In patients who have not had these diseases, particular care should be taken to avoid exposure. After exposure, prophylaxis with varicella zoster immune globulin (chickenpox) or pooled intramuscular immunoglobulin (measles) may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.
- Elevation of blood pressure and salt and water retention: Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium; these effects are less likely with the synthetic derivatives except in large doses. All corticosteroids increase calcium excretion. Dietary salt restriction and potassium supplementation may be necessary. Use with caution in congestive heart failure, hypertension, or renal insufficiency.
- Left ventricular free wall rupture: Literature reports suggest an apparent association between corticosteroids and left ventricular free wall rupture after a recent myocardial infarction, so corticosteroids should be used with great caution in these patients.
- Gastrointestinal perforation: Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation after perforation may be minimal or absent. Gastric irritation may be reduced if doses are taken before, during, or immediately after meals or with food or milk, and antacids between meals are recommended when large doses are given.
- Osteoporosis: Corticosteroids decrease bone formation and increase bone resorption, which may lead to inhibition of bone growth in pediatric patients and osteoporosis at any age. Give special consideration to patients at increased risk of osteoporosis (e.g., postmenopausal women) before therapy, and use the smallest possible effective dosage and duration to minimize glucocorticoid-induced bone loss.
- Acute myopathy: An acute myopathy has been observed with high doses of corticosteroids, most often in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) or on neuromuscular blocking drugs (e.g., pancuronium). It is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur, and recovery after stopping corticosteroids may require weeks to years.
- Psychiatric derangements: Psychiatric derangements may appear, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Existing emotional instability or psychotic tendencies may be aggravated.
- Dose-dependent complications: The lowest possible dose of corticosteroids should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual. Since complications of treatment depend on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each case as to dose, duration, and daily or intermittent therapy.
- Kaposi's sarcoma: Kaposi's sarcoma has been reported in patients receiving corticosteroid therapy, most often for chronic conditions; discontinuation of corticosteroids may result in clinical improvement.
Common Side Effects
The label lists reactions reported with prednisone or other corticosteroids, without rates. Ocular reactions include posterior subcapsular cataracts, glaucoma, optic nerve damage, increased intraocular pressure, central serous chorioretinopathy, blurred vision, exophthalmos, papilledema, and secondary bacterial, fungal and viral infections. Systemic ones include adrenal insufficiency, cushingoid state, hyperglycemia and new-onset diabetes mellitus, growth suppression in children, sodium retention with edema, hypertension, osteoporosis, pathologic fracture, aseptic necrosis of femoral and humeral heads, steroid myopathy, tendon rupture, peptic ulcer with possible perforation and hemorrhage, pancreatitis, insomnia, mood swings, euphoria, depression, steroid psychoses, increased intracranial pressure with papilledema usually following discontinuation, and decreased resistance to infection.
Pregnancy: Category C on this label. Teratogenic in many species at doses equivalent to the human dose, with increased cleft palate in mice, rats, and rabbits; no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received substantial doses during pregnancy should be carefully observed for signs of hypoadrenalism.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Efficacy and safety in children rest on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations; published studies support use in nephrotic syndrome (patients >2 years of age) and aggressive lymphomas and leukemias (patients >1 month of age). Adverse effects are similar to those in adults; observe blood pressure, weight, height, intraocular pressure, and clinical signs of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Growth velocity may decrease, even at low systemic doses and without laboratory evidence of HPA axis suppression; monitor linear growth and titrate to the lowest effective dose.